Latest Breaking News On - For cytomx - Page 1 : comparemela.com

27.03.2023 - - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers .

United statesChris ogdenSean mccarthyStephanie ascherBristol myers squibbCytomx therapeutics incProbodyt cell bispecificProbodyt cellQuarter business highlightsWholly ownedFor cytomxUpdated phaseAmgen agreementCytomx therapeuticsProbody platformAnnual report